Hosted on MSN1d
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment
Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...
Lilly signs licensing deal with Mediar for IPF drug
Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...
FierceBiotech4d
Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...
The Pharma Letter1d
Mediar Therapeutics inks IPF deal with Lilly
US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli ...
Contract Pharma4d
Mediar, Lilly Enter Global Licensing Agreement for WISP1 Antibody
A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.
BioSpace4d
Lilly Makes $780M+ IPF Play with Mediar Partnership
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...